Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-79032421 |
| Synonyms | |
| Therapy Description |
JNJ-79032421 is a bispecific antibody targeting the membrane-restricted region of MSLN and CD3, which potentially induces killing of tumor cells expressing MSLN and inhibits tumor growth (Eur J Cancer 211 (2024): 114666). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-79032421 | JNJ 79032421|JNJ79032421 | CD3 Antibody 119 MSLN Antibody 13 | JNJ-79032421 is a bispecific antibody targeting the membrane-restricted region of MSLN and CD3, which potentially induces killing of tumor cells expressing MSLN and inhibits tumor growth (Eur J Cancer 211 (2024): 114666). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06255665 | Phase I | JNJ-79032421 | A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors | Completed | ESP | 0 |